

### **Amendments To The Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

#### **Listing of Claims:**

1. (cancelled)
2. (Previously Presented) Neotheaflavate B or a salt or an ester thereof.
3. (Previously Presented) EGCGCa (Epigallocatechinocatechol gallate) or a salt or an ester thereof.
4. (Previously Presented) A composition comprising the neotheaflavate B or a salt or an ester thereof of claim 2.
5. (Previously Presented) A composition comprising the EGCGCa or a salt or an ester thereof of claim 3.
6. (Previously Presented) The composition of claim 5, further comprising a pharmaceutically acceptable carrier or diluent, wherein said composition is effective as an anti-inflammatory agent or antioxidant.
7. (Previously Presented) The composition of claim 5, wherein the composition is a nutraceutical and is effective as an anti-inflammatory agent or antioxidant.
8. (Previously Presented) The composition of claim 4, wherein the composition is a

nutraceutical and is effective as an anti-inflammatory agent or antioxidant.

9. (Previously Presented) The composition of claim 4, further comprising a pharmaceutically acceptable carrier or diluent, wherein said composition is effective as an anti-inflammatory agent or antioxidant.

10. (Previously Presented) A method for treating an inflammatory condition comprising administering to a subject in need thereof a composition comprising an amount of (i) neotheaflavate B, a salt or an ester thereof; or (ii) EGCGCa (epigallocatechinocatechol gallate), a salt or an ester thereof, wherein said amount is effective to treat the inflammatory condition.

11. (Previously Presented) The method according to claim 10 wherein said amount is at a dosage of between about 0.5 and about 1000 mg per kilogram body weight per day.

12. (Previously Presented) The method according to claim 10 wherein said amount is at a dosage of between about 1 and about 500 mg per kilogram body weight per day.

13. (Previously Presented) The method according to claim 10 wherein said composition is administered topically.

14. (Previously Presented) The method according to claim 10 wherein said composition is administered orally.

15. (Previously Presented) The method according to claim 10 wherein said

composition is administered parenterally.

16. (Previously Presented) A method of treating or reducing the progression of an inflammatory condition comprising administering to a subject in need thereof a composition comprising an effective amount of (i) neotheaflavate B, a salt or an ester thereof; or (ii) EGCGCa (epigallocatechinocatechol gallate), a salt or an ester thereof, and a carrier selected from the group consisting of a pharmaceutically acceptable carrier, veterinary acceptable carrier, dietary supplement carrier and food.

17. (original) The method of claim 16, wherein the carrier is a pharmaceutically acceptable carrier.

18. (original) The method of claim 16, wherein the subject is a human.

19. (original) The method of claim 16, wherein the carrier is a food.

20. (original) The method of claim 16, in which the composition is a dietary supplement.

21. (Previously Presented) A method for neutralizing free radicals in a patient comprising: administering to the patient in need of such treatment a composition comprising an effective amount of (i) neotheaflavate B, a salt or an ester thereof; or (ii) EGCGCa (epigallocatechinocatechol gallate), a salt or an ester thereof

22. (Previously Presented) The method of claim 21, wherein the neotheaflavate B or EGCGCa (epigallocatechinocatechol gallate), a salt or an ester thereof is present at a concentration of at least about 0.5%.

23. (Previously Presented) The method of claim 21, wherein the composition comprises neotheaflavate B, a salt or an ester thereof.

24. (Previously Presented) The method of claim 21, wherein the composition comprises EGCGCa (epigallocatechinocatechol gallate), or a salt or an ester thereof.

25. (Previously Presented) The method of claim 21, wherein the composition comprises a carrier selected from the group consisting of a pharmaceutically acceptable carrier, veterinary acceptable carrier, dietary supplement carrier and food.

26.-45. (cancelled)

46. (Previously Presented) The neotheaflavate B, a salt or an ester thereof of claim 2, which is purified.

47. (Previously Presented) The EGCGCa (Epigallocatechinocatechol gallate), a salt or an ester thereof of claim 3, which is purified.

48 (cancelled).